- Proceeds to Fund Advancement of Company’s Pipeline of Protease Activated T-Cell Engagers and Cytokines for Solid Tumor Treatment
- Funding round backed by a syndicate of leading cross-investors including Viking Global Investors, Bain Capital Life Sciences, BlackRock, Franklin Templeton, Janus Henderson Investors, Redmile Group and other investors
SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) – Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing masked immuno-oncology therapies activated by protease to deliver the promise of these potent therapies for patients with solid tumor cancers, today announced it has raised $ 117 million in Series B funding. The funding round was led by Viking Global Investors with participation from a premier syndicate of funds. plan, including new investors Bain Capital Life Sciences, BlackRock, Franklin Templeton, Janus Henderson Investors, ArrowMark Partners, Avidity Partners, certain funds managed by Clough Capital Partners, and CaaS Capital Management. Existing investors Redmile Group, Venrock, Casdin Capital, Omega Funds, Frazier Healthcare Partners, Longitude Capital and Polaris Partners also participated in the round.
Proceeds from the funding will fund the clinical advancement of AMX-818, a protease-activated masked T cell activator (XPAT®) targeting solid tumors expressing HER2, as well as supporting the robust Immunix pipeline of early-stage XPAT® and protease activated masked cytokines (XPACs ™).
“We are delighted to partner with investors who support our vision and innovative approach as we strive to realize the potential of T cell activators and cytokines and dramatically improve outcomes for cancer patients,” said Angie You, Ph.D., CEO of Amunix. “We are building on the promise of these potent drugs to target and attack solid tumors, while potentially reducing their toxicity. Although widely recognized as potent anti-tumor agents, to-target and disabled-tumor toxicity of unmasked T cell activator and cytokine therapies has limited their usefulness. Our XTEN® polymer technology with significant human validation is the foundation of our XPAT® and the XPAC ™ platforms, allowing XTEN® to serve as a universal protease-releasing mask for preferential activation in the tumor microenvironment. Our platform delivers next-generation plug and play masking technology that we have leveraged to create a robust pipeline and rapidly advance new drug candidates through discovery and optimization.
About the Amunix platform
Amunix relies on its proprietary Pro-XTEN® technology platform to create potent immune modulator drugs that are preferentially activated in the high protease medium of the tumor microenvironment to cause tumor cell death while minimizing toxicity elsewhere in the body. The technology consists of two proprietary components: 1) a mask, which is an unstructured polypeptide (XTEN®) clinically validated to have low immunogenicity, which functions via steric hindrance and confers extended half-life, and 2) a protease release site which allows mask release and therefore drug activation, by proteases associated with the tumor. The proprietary molecules of Amunix are called XTENylé Protease-Aactivated T XPAT cell engageers®) and XTENylé Protease-Aactivated hidden VSytokines (XPACs ™).
About Immunix Pharmaceuticals
Amunix Pharmaceuticals, based in South San Francisco, California, is focused on the development of masked T cell activators and cytokines to bring the promise of these potent immune-activating biotherapeutics to patients with solid tumor cancers. The company leverages its proprietary XPAT® and the XPAC ™ platforms to advance a pipeline of new drugs that are preferentially activated in the tumor microenvironment and designed to overcome toxicity issues that have hampered other T cell and cytokine therapies. Immunix’s proprietary masking technology has been clinically validated to extend the half-life of the drug with limited immunogenicity. The company’s pipeline includes AMX-818, an XPAT® Commitment of T cells targeting a variety of solid tumors expressing HER2, which is currently the subject of studies enabling IND. Along with several other T cell activation programs, Amunix is also applying its proprietary masking technology to its first protease-activated masked cytokine program, IL12-XPAC ™, which is in the discovery phase.
For more information about the company, please visit www.amunix.com.
Company details :
Director, Corporate Development